NVX-CoV2373 vaccine is filed for Emergency Use Authorization to prevent COVID 19 in Taiwan. Novavax
Novavax announced the submission of a request for emergency use authorization to Taiwan’s Food and Drug Administration for its COVID-19 vaccine, NVX-CoV2373, for active immunization against SARS-CoV-2 in individuals aged 18 and over.
The submission includes data from two pivotal Phase III clinical trials: PREVENT-19, which enrolled approximately 30,000 participants aged 18 years and older in the U.S. and Mexico and was published in the New England Journal of Medicine (NEJM) (previously cited); and a UK-based trial with almost 15,000 adult participants, also published in NEJM. In both trials, the vaccine demonstrated efficacy with a reassuring safety profile.
See also: "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine"; P.T. Heath and Others.February 10, 2022. N Engl J Med 2022; 386:531-543.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins